11/18
06:18 am
sln
Silence Therapeutics: Divesiran Targets High-Burden PV [Seeking Alpha]
Low
Report
Silence Therapeutics: Divesiran Targets High-Burden PV [Seeking Alpha]
11/12
08:00 am
sln
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Low
Report
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
11/9
07:43 am
sln
Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates [Yahoo! Finance]
Medium
Report
Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates [Yahoo! Finance]
11/6
07:30 am
sln
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Low
Report
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
10/23
07:30 am
sln
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Low
Report
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
10/8
12:35 pm
sln
Silence Therapeutics (NASDAQ:SLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Silence Therapeutics (NASDAQ:SLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/16
08:07 am
sln
Silence Therapeutics (NASDAQ:SLN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Silence Therapeutics (NASDAQ:SLN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.